PT-141 (Bremelanotide) vs BPC-157
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Recovery & Repair
BPC-157- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Half-Life
- 2–3 hours
- 4–6 hours
- Admin Route
- SubQ
- SubQ, IM, Oral
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 200–500 mcg
- Frequency
- As needed (not daily)
- Once daily
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Stacks With
- —
- —